Heron Therapeutics Inc (NASDAQ:HRTX) has earned an average rating of “Buy” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $55.50.
Several equities research analysts have recently weighed in on HRTX shares. BidaskClub upgraded shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 27th. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 price objective on shares of Heron Therapeutics in a research report on Monday, December 31st. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective (down from $66.00) on shares of Heron Therapeutics in a research report on Wednesday, January 16th.
NASDAQ HRTX traded up $0.78 on Monday, hitting $23.50. The company’s stock had a trading volume of 1,056,470 shares, compared to its average volume of 876,981. Heron Therapeutics has a 1-year low of $21.25 and a 1-year high of $42.90. The stock has a market cap of $1.84 billion, a P/E ratio of -9.63 and a beta of 1.55.
Several institutional investors and hedge funds have recently bought and sold shares of HRTX. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Heron Therapeutics by 24.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 929 shares in the last quarter. Jefferies Group LLC bought a new position in Heron Therapeutics during the third quarter worth $202,000. Verition Fund Management LLC bought a new position in Heron Therapeutics during the third quarter worth $208,000. Stephens Inc. AR bought a new position in Heron Therapeutics during the fourth quarter worth $208,000. Finally, Pacer Advisors Inc. bought a new position in Heron Therapeutics during the third quarter worth $223,000.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More: Investing in Growth Stocks
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.